SEC Form 4 · accession 0001209191-16-099415
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mihael Hristos Polymeropoulos
Officer — President and CEO · Director
Period of report
Feb 12, 2016
Accepted (ET)
Feb 17, 2016 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $7.94 | Feb 12, 2016 | A | 175,000 | A | — | Feb 11, 2026 | Common Stock | 175,000 | 175,000 | D |
| Restricted Stock UnitF2,F3,F4 | — | Feb 12, 2016 | A | 75,000 | A | — | — | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The shares subject to this option shall vest in forty-eight (48) equal monthly installments beginning March 12, 2016, provided Reporting Person remains continuously employed by the Issuer through each monthly vesting date.
- F2Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock.
- F3The RSUs shall vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissable Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- F4Not Applicable.